Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

David J. Straus, Sin-Ho Jung, Brandelyn Pitcher, Lale Kostakoglu, John C. Grecula, Eric D. Hsi, Heiko Schöder, Leslie L. Popplewell, Julie E. Chang, Craig H. Moskowitz, Nina Wagner-Johnston, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl, Bruce D. Cheson, Nancy L. Bartlett

Blood (2018) 132 (10): 1013–1021.

https://doi.org/10.1182/blood-2018-01-827246

Published: 2018

Includes: Supplemental data

Journal Articles

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Chaitra S. Ujjani, Sin-Ho Jung, Brandelyn Pitcher, Peter Martin, Steven I. Park, Kristie A. Blum, Sonali M. Smith, Myron Czuczman, Matthew S. Davids, Ellis Levine, Lionel D. Lewis, Scott E. Smith, Nancy L. Bartlett, John P. Leonard, Bruce D. Cheson

Blood (2016) 128 (21): 2510–2516.

https://doi.org/10.1182/blood-2016-06-718106

Published: 2016

Journal Articles

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

David J. Straus, MD, Brandelyn Pitcher, MS, Lale Kostakoglu, MD MPH, John C Grecula, MD, Eric D. Hsi, MD, Heiko Schoder, MD, Sin-Ho Jung, PhD, Leslie L. Popplewell, MD, Julie E Chang, MD, Craig H Moskowitz, MD, Nina Wagner-Johnson, MD, John P. Leonard, MD, Jonathan W. Friedberg, MD MMSc, Brad S Kahl, MD, Bruce D. Cheson, MD, Nancy L. Bartlett, MD

Blood (2015) 126 (23): 578.

https://doi.org/10.1182/blood.V126.23.578.578

Published: 2015

Journal Articles

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

Lawrence D. Kaplan, MD, Sin-Ho Jung, PhD, Wendy Stock, MD, Nancy L. Bartlett, MD, Brandelyn Pitcher, MS, John C. Byrd, MD, Kristie A. Blum, MD, Ann S. LaCasce, MD, Noreen Fulton, Eric D. Hsi, MD, David D Hurd, MD, Myron Czuczman, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 337.

https://doi.org/10.1182/blood.V126.23.337.337

Published: 2015

Journal Articles

Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Chaitra S. Ujjani, MD, Sin-Ho Jung, PhD, Brandelyn Pitcher, MS, Peter Martin, MD, Steven I. Park, MD, Kristie A. Blum, MD, Sonali M. Smith, MD, Myron S. Czuczman, MD, Matthew S. Davids, MD, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 471.

https://doi.org/10.1182/blood.V126.23.471.471

Published: 2015

Journal Articles

Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Cara A. Rosenbaum, MD, Brandelyn Pitcher, MS, Nancy L Bartlett, MD, Sonali M. Smith, MD, Jane Jijun Liu, MD, Eric D. Hsi, MD, Sin-Ho Jung, PhD, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 2741.

https://doi.org/10.1182/blood.V126.23.2741.2741

Published: 2015

Journal Articles

Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202

Sonali M. Smith, MD, Brandelyn Pitcher, MS, Sin-Ho Jung, PhD, Nancy L. Bartlett, MD, Nina Wagner-Johnston, MD, Steven I. Park, MD, Kristy L. Richards, MDPhD, Amanda F. Cashen, MD, Bruce D. Cheson, MD, John P. Leonard, MD

Blood (2014) 124 (21): 3091.

https://doi.org/10.1182/blood.V124.21.3091.3091

Published: 2014

NARROW

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202

Email alerts

ASH Publications

American Society of Hematology

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only